KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Equity Ratio: 2009-2025

Historic Equity Ratio for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to 0.80.

  • Biomarin Pharmaceutical's Equity Ratio rose 0.66% to 0.80 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.80, marking a year-over-year increase of 0.66%. This contributed to the annual value of 0.81 for FY2024, which is 11.86% up from last year.
  • Biomarin Pharmaceutical's Equity Ratio amounted to 0.80 in Q3 2025, which was down 1.60% from 0.81 recorded in Q2 2025.
  • Biomarin Pharmaceutical's Equity Ratio's 5-year high stood at 0.81 during Q1 2025, with a 5-year trough of 0.71 in Q4 2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Equity Ratio value was 0.75 (recorded in 2024), while the average stood at 0.76.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Equity Ratio rose by 17.80% in 2021, and later declined by 0.65% in 2023.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Equity Ratio stood at 0.71 in 2021, then increased by 1.64% to 0.72 in 2022, then increased by 0.23% to 0.72 in 2023, then rose by 11.86% to 0.81 in 2024, then increased by 0.66% to 0.80 in 2025.
  • Its Equity Ratio was 0.80 in Q3 2025, compared to 0.81 in Q2 2025 and 0.81 in Q1 2025.